| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.8 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |
| mRNA | GDC-0449 | FIMM | pan-cancer | AAC | 0.045 | 0.8 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | 0.041 | 0.8 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |